French biotech’s top­i­cal pain treat­ment fails Phase 2 study with over­per­form­ing place­bo

Al­go­Ther­a­peu­tix’s top­i­cal non-opi­oid drug has flunked a mid-stage tri­al in chemother­a­py-in­duced pain due to a stronger-than-ex­pect­ed place­bo arm, but the com­pa­ny is still de­ter­mined to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER